Molecular Response announced that Brett Hall will be its new CEO and will lead the firm's repositioning as a drug development company. As Molecular Response Therapeutics, the firm will develop treatments that interrogate tumor cell interactions "with permissive host tumor microenvironments," the company said in a statement.
Hall previously led the oncology translational medicine group within AstraZeneca subsidiary MedImmune. Before that, he was in charge of the hematologic oncology group at J&J, where he oversaw multiple drug programs. In these roles, Hall was involved in advancing more than 20 cancer drugs from early- to late-stage development. He also worked on biomarker discovery, market segmentation, and companion diagnostics.